284 related articles for article (PubMed ID: 28657400)
1. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use.
Singh VK; Hanlon BK; Santiago PT; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):885-906. PubMed ID: 28657400
[TBL] [Abstract][Full Text] [Related]
2. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
Singh VK; Garcia M; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
[TBL] [Abstract][Full Text] [Related]
3. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
Singh VK; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
[TBL] [Abstract][Full Text] [Related]
4. Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.
Singh VK; Romaine PL; Seed TM
Health Phys; 2015 Jun; 108(6):607-30. PubMed ID: 25905522
[TBL] [Abstract][Full Text] [Related]
5. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
Singh VK; Romaine PL; Newman VL; Seed TM
Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
[TBL] [Abstract][Full Text] [Related]
6. Nonhuman primates as models for the discovery and development of radiation countermeasures.
Singh VK; Olabisi AO
Expert Opin Drug Discov; 2017 Jul; 12(7):695-709. PubMed ID: 28441902
[TBL] [Abstract][Full Text] [Related]
7. Medical countermeasures for unwanted CBRN exposures: Part I chemical and biological threats with review of recent countermeasure patents.
Singh VK; Garcia M; Wise SY; Seed TM
Expert Opin Ther Pat; 2016 Dec; 26(12):1431-1447. PubMed ID: 27599259
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems.
Singh VK; Seed TM
Expert Opin Pharmacother; 2020 Feb; 21(3):317-337. PubMed ID: 31928256
[No Abstract] [Full Text] [Related]
9. The efficacy and safety of amifostine for the acute radiation syndrome.
Singh VK; Seed TM
Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
[No Abstract] [Full Text] [Related]
10. A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute.
Singh VK; Ducey EJ; Brown DS; Whitnall MH
Int J Radiat Biol; 2012 Apr; 88(4):296-310. PubMed ID: 22191567
[TBL] [Abstract][Full Text] [Related]
11. Biologics as countermeasures for acute radiation syndrome: where are we now?
Singh VK; Romaine PL; Newman VL
Expert Opin Biol Ther; 2015 Apr; 15(4):465-71. PubMed ID: 25416452
[TBL] [Abstract][Full Text] [Related]
12. Radiation countermeasure agents: an update (2011-2014).
Singh VK; Newman VL; Romaine PL; Wise SY; Seed TM
Expert Opin Ther Pat; 2014 Nov; 24(11):1229-55. PubMed ID: 25315070
[TBL] [Abstract][Full Text] [Related]
13. Animal models and medical countermeasures development for radiation-induced lung damage: report from an NIAID Workshop.
Williams JP; Jackson IL; Shah JR; Czarniecki CW; Maidment BW; DiCarlo AL
Radiat Res; 2012 May; 177(5):e0025-39. PubMed ID: 22468702
[TBL] [Abstract][Full Text] [Related]
14. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation countermeasures.
Mishra KN; Moftah BA; Alsbeih GA
Biomed Pharmacother; 2018 Oct; 106():610-617. PubMed ID: 29990850
[TBL] [Abstract][Full Text] [Related]
15. γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.
Singh VK; Hauer-Jensen M
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27153057
[TBL] [Abstract][Full Text] [Related]
16. Product Development within the National Institutes of Health Radiation and Nuclear Countermeasures Program.
Cassatt DR; DiCarlo AL; Molinar-Inglis O
Radiat Res; 2024 May; 201(5):471-478. PubMed ID: 38407357
[TBL] [Abstract][Full Text] [Related]
17. Protecting people against radiation exposure in the event of a radiological attack. A report of The International Commission on Radiological Protection.
Valentin J;
Ann ICRP; 2005; 35(1):1-110, iii-iv. PubMed ID: 16164984
[TBL] [Abstract][Full Text] [Related]
18. Modifiers of radiation effects in the eye.
Kleiman NJ; Stewart FA; Hall EJ
Life Sci Space Res (Amst); 2017 Nov; 15():43-54. PubMed ID: 29198313
[TBL] [Abstract][Full Text] [Related]
19. Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond.
Singh VK; Seed TM
Int J Radiat Biol; 2021; 97(11):1526-1547. PubMed ID: 34402734
[TBL] [Abstract][Full Text] [Related]
20. Development and licensure of medical countermeasures to treat lung damage resulting from a radiological or nuclear incident.
DiCarlo AL; Jackson IL; Shah JR; Czarniecki CW; Maidment BW; Williams JP
Radiat Res; 2012 May; 177(5):717-21. PubMed ID: 22468704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
